Cargando…

Disease burden of varicella versus other vaccine-preventable diseases before introduction of vaccination into the national immunisation programme in the Netherlands

INTRODUCTION: Estimating burden of disease (BoD) is an essential first step in the decision-making process on introducing new vaccines into national immunisation programmes (NIPs). For varicella, a common vaccine-preventable disease, BoD in the Netherlands was unknown. AIM: To assess national varice...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Lier, Alies, de Gier, Brechje, McDonald, Scott A, Mangen, Marie-Josée J., van Wijhe, Maarten, Sanders, Elisabeth A.M., Kretzschmar, Mirjam E., van Vliet, Hans, de Melker, Hester E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Centre for Disease Prevention and Control (ECDC) 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505181/ https://www.ncbi.nlm.nih.gov/pubmed/31064637 http://dx.doi.org/10.2807/1560-7917.ES.2019.24.18.1800363

Ejemplares similares

Hospitalization due to varicella in the Netherlands
por: van Lier, Alies, et al.
Publicado: (2011)

Disease Burden of 32 Infectious Diseases in the Netherlands, 2007-2011
por: van Lier, Alies, et al.
Publicado: (2016)

Intention to vaccinate universally against varicella, rotavirus gastroenteritis, meningococcal B disease and seasonal influenza among parents in the Netherlands: an internet survey
por: van Lier, Alies, et al.
Publicado: (2017)

Negative attitude and low intention to vaccinate universally against varicella among public health professionals and parents in the Netherlands: two internet surveys
por: van Lier, Alies, et al.
Publicado: (2016)

Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020
por: Middeldorp, Marit, et al.
Publicado: (2021)

Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands
por: van Lier, Alies, et al.
Publicado: (2010)

Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster
por: van Lier, Alies, et al.
Publicado: (2015)

Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines
por: de Boer, Pieter T., et al.
Publicado: (2018)

Transmissibility of SARS-CoV-2 among fully vaccinated individuals
por: Knol, Mirjam J, et al.
Publicado: (2022)

Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022
por: van Iersel, Senna C.J.L., et al.
Publicado: (2023)

Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022
por: Hoeve, Christina E, et al.
Publicado: (2023)

Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
por: Huiberts, Anne J, et al.
Publicado: (2023)

The dynamics of scarlet fever in The Netherlands, 1906–1920: a historical analysis
por: McDonald, Scott A., et al.
Publicado: (2022)

The impact of demographic change on the estimated future burden of infectious diseases: examples from hepatitis B and seasonal influenza in the Netherlands
por: McDonald, Scott A, et al.
Publicado: (2012)

Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021–January 2022
por: de Gier, Brechje, et al.
Publicado: (2023)

Assessment of vaccine candidates for persons aged 50 and older: a review
por: Eilers, Renske, et al.
Publicado: (2013)

COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021
por: van Ewijk, Catharina E, et al.
Publicado: (2022)

Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands
por: Thorrington, Dominic, et al.
Publicado: (2018)

Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study
por: Huiberts, Anne J., et al.
Publicado: (2023)

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands
por: Knol, Mirjam J., et al.
Publicado: (2015)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
por: van Deursen, Anna M.M., et al.
Publicado: (2012)

Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018
por: Knol, Mirjam J, et al.
Publicado: (2018)

Socioeconomic Status Is Associated With Antibody Levels Against Vaccine Preventable Diseases in the Netherlands
por: Hoes, Joske, et al.
Publicado: (2018)

Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015
por: Wagenvoort, Gertjan H J, et al.
Publicado: (2017)

Regional differences in historical diphtheria and scarlet fever notification rates in The Netherlands, 1905–1925: a spatial-temporal analysis
por: McDonald, Scott A., et al.
Publicado: (2023)

Determinants of HPV-vaccination uptake and subgroups with a lower uptake in the Netherlands
por: de Munter, A. C., et al.
Publicado: (2021)

Epidemic of Mumps among Vaccinated Persons, the Netherlands, 2009–2012
por: Sane, Jussi, et al.
Publicado: (2014)

Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology
por: de Gier, Brechje, et al.
Publicado: (2023)

Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis
por: Nic Lochlainn, Laura M, et al.
Publicado: (2019)

Higher risk of SARS-CoV-2 Omicron BA.4/5 infection than of BA.2 infection after previous BA.1 infection, the Netherlands, 2 May to 24 July 2022
por: Andeweg, Stijn P, et al.
Publicado: (2023)

Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis
por: Nic Lochlainn, Laura M, et al.
Publicado: (2019)

Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021
por: de Gier, Brechje, et al.
Publicado: (2021)

Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
por: Ohm, Milou, et al.
Publicado: (2021)

An evidence synthesis approach to estimating the incidence of symptomatic pertussis infection in the Netherlands, 2005–2011
por: McDonald, Scott A., et al.
Publicado: (2015)

Increase in invasive disease caused by Haemophilus influenzae b, the Netherlands, 2020 to 2021
por: Steens, Anneke, et al.
Publicado: (2021)

A Software Tool for Estimation of Burden of Infectious Diseases in Europe Using Incidence-Based Disability Adjusted Life Years
por: Colzani, Edoardo, et al.
Publicado: (2017)

Determinants of COVID-19 Vaccine Uptake in The Netherlands: A Nationwide Registry-Based Study
por: Pijpers, Joyce, et al.
Publicado: (2023)

Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013
por: Cassini, Alessandro, et al.
Publicado: (2018)

An exploratory qualitative assessment of factors influencing childhood vaccine providers' intention to recommend immunization in the Netherlands
por: Mollema, Liesbeth, et al.
Publicado: (2012)

Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands
por: Rodenburg, Gerwin D., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_q5pktfso0b2fcuj2nlle1r7f8i